Claim OwnershipPODCAST-19: FiveThirtyEight on the Novel Coronavirus
Subscribed: 1,765Played: 36,392
Subscribe
© Copyright 2021, ABC Audio. All rights reserved.
Description
FiveThirtyEight's COVID-19 podcast is laser-focused on evidence. What do we know about the novel coronavirus, and what do we know we don't know? COVID-19 has pushed Americans into more uncertain territory than most have ever known. Our podcast helps listeners understand what they can be certain about, and what is still unknown. We investigate coronavirus mysteries, debate when it's safe to reopen the economy and keep track of the latest scientific developments on vaccines and treatments. We do it all with FiveThirtyEight's trademark blend of transparency and rigor.
46 Episodes
Reverse
But podcasts about them do. We're sad to report this is the final episode of PODCAST-19! It's been so rewarding making a show for you over the past year. In this episode, we discuss why we're closing up shop and why pandemics are so hard to beat.
The CDC wants to be certain, so it typically waits for a critical mass of scientific evidence before making declarative statements. That takes time. Yet the communication to the public in this pandemic seemed to be worse than normal, and resulted in a huge loss of public trust. Over the past month, we spoke to nearly a dozen scientists who all agreed the CDC could have done better. But the root causes of the CDC’s shortcomings will be hard to fix.
1We have no hard evidence to support the idea that the novel coronavirus was leaked from a lab, let alone a smoking gun to validate that hypothesis. But despite pushback on this story from many scientists and the media early on, it’s back in the news, and many are talking about the possibility of a lab leak. There may be some legitimate reasons to do more digging, but the debate has gotten heated. And when a conversation is centered around controversy, instead of science, we can lose sight of the bigger, more important picture.
There's a worldwide shortage of vaccines but plenty of factories standing by to make them. Why is there such a gap between what we need and what we can make? On this week's episode, we explore the surprisingly wild world of pharmaceutical patent law to understand how our system came to be and how it has shaped the pandemic.
Kids can't get a COVID-19 vaccination yet, but they're unlikely to develop serious complications from the disease. But they can still be vectors to spread COVID-19 to others who are likely to get very sick. On this week's episode, we look into how big of a risk unvaccinated kids pose to society, and what parents should keep in mind.
We've learned time and again that animals can give diseases to humans. We've seen this happen with coronaviruses, the flu, Ebola -- basically most major disease outbreaks in recent memory. But, of course, the reverse is true too: Humans can give viruses, including the novel coronavirus, to animals. FiveThirtyEight’s senior science writer Maggie Koerth wrote about this on the site earlier this week, and she joined PODCAST-19, FiveThirtyEight’s coronavirus podcast, to discuss her work further.
The United States has a surplus of COVID-19 vaccines — more than enough to vaccinate every adult. Poor countries, however, are still struggling to secure doses. Should those vaccines be sent to countries in need? If not, who will do the sending? And should rich countries profit off the exchange?
Federal health agencies asked states to pause in their use of the Johnson & Johnson vaccine while U.S. officials investigate reports of an extremely rare blood-clotting syndrome that has developed in six people who have received the vaccine. Given how few people are sick, why did the U.S. recommend a pause? And what's it say about how the monitoring system is working?
The AstraZeneca COVID-19 vaccine has been hailed as the world’s vaccine -- it’s inexpensive to produce and doesn’t need super-cold storage like the mRNA vaccines do. But its rollout has been messy. Will its missteps erode the public's (or the FDA's) trust? Maggie Koerth joins to discuss.
At some point, the U.S. is going to run out of people eager to get the vaccine, and we’ll need to work hard to convert those who are still hesitant or don’t know how to get it. It won’t be the first time we’ve done so. For months, community leaders have been working to overcome transportation challenges, language barriers, and digital divides. We speak to five of those leaders on this week's episode to hear how they convinced people to get the vaccine, and what that might mean for the months to come.
On this week's show, we discuss what the endgame of the pandemic will be. It likely isn't herd immunity. And if herd immunity isn't the goal, does that change how people should behave once they're vaccinated? We have a science-backed guide for how to evaluate what's risky and what's safe among the vaccinated.
Coronavirus mutations have complicated our path forward. But that doesn’t mean that our current plan out of the pandemic is futile.
Should you take a leftover vaccine? Should you pass up a vaccine if you think you don't need it as much as someone else does? We talk to bioethicists to get their answers on these questions and more.
Anna talks with Dr. Margaret Liu, one of the pioneers of gene-based vaccines, about vaccines that use mRNA to help us build immunity to COVID-19, including the Pfizer-BioNTech and Moderna vaccines. How is this method different from vaccines in the past, and what does the mRNA do once it gets inside our bodies?
There are so many questions about a COVID-19 vaccine that we didn't know where to begin. So we began with you! We took to the mailbag to find answers on vaccine availability, immunity, and more.
On the first day of Christmas, PODCAST-19 gave to me ... an interview with Dr. Fauci.
Dr. Anthony Fauci stops by the pod to talk about post-vaccine life, the new variant of the virus in the U.K. and which celebrity he'd like to see vaccinated.
Data has been such a valuable commodity during the pandemic. Unfortunately, at times data has been in short supply, because US government agencies haven’t always undertaken national data collection efforts. So what happens when individuals citizens try to collect data themselves? We talk to Professor Emily Oster, who developed a national COVID-19 School Response Dashboard, to find out what she’s learned about COVID in schools, the implications of volunteers developing their own public health trackers, and how she thinks the Biden administration will approach pandemic data collection.
It feels like a cure for this pandemic may be in sight. But for many people, injecting a brand-new scientific discovery into their body won't sit well. So, how are scientists making sure that a COVID-19 vaccine won’t cause more damage than the disease? How do regulators decide what an acceptable side effect is? And what would happen if someone did have a serious reaction to the COVID vaccine after it was released? This week, we’re devoting our whole show to vaccine safety.
Our producer, Sinduja Srinivasan, reports on long COVID, and how our health care system might cope with so many patients with ongoing symptoms.
This week, Pfizer announced that its coronavirus vaccine may be more than 90 percent effective. Anna and FiveThirtyEight's senior science writer, Maggie Koerth, discuss what we know (and don't know) about about the vaccine.
Download from Google Play
Download from App Store
United States
🤣🤣🥵just jumped from animals to humans .. lol ok
thank you for this episode! it was extremely informative and even a bit reassuring.
oo o look pplo o on p
Great series.